Cerivastatin-induced apoptosis of human aortic smooth muscle cells through partial inhibition of basal activation of extracellular signal-regulated kinases

Cardiovascular Pathology

Volumn 13, Issue 1, 2004, Pages 41-48

  Takata, Ryu ^a,b   Fukasawa, Shinya ^b   Hara, Takeshi ^b   Nakajima, Hitoshi ^b   Yamashina, Akira ^b   Yanase, Noriko ^a   Mizuguchi, Junichiro ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

^b TOKYO MEDICAL UNIVERSITY HOSPITAL   (Japan)

Author keywords

Apoptosis; Cerivastatin; ERK; Human; Smooth muscle cell

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ANTIBODY; CERIVASTATIN; FARNESYL DIPHOSPHATE; GERANYLGERANYL PYROPHOSPHATE; ISOPRENOID; MEVALONIC ACID; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PROPIDIUM IODIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; STRESS ACTIVATED PROTEIN KINASE; TRYPAN BLUE;

AORTA; APOPTOSIS; ARTICLE; CELL CULTURE; CELL GROWTH; CELL VIABILITY; COLORIMETRY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME REGULATION; FLOW CYTOMETRY; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER; WESTERN BLOTTING;

EID: 0842326546     PISSN: 10548807     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1054-8807(03)00104-2     Document Type: Article

References (38)

1. Chong P.H., Seeger J.D., Franklin C. Clinically relevant differences between the statins: implications for therapeutic selection. Am J Med. 111:2001;390-400.
2. Blumenthal R.S. Statins: effective antiatherosclerotic therapy. Am Heart J. 139:2000;577-583.
3. Corsini A., Bellosta S., Baetta R., Fumagalli R., Paoletti R., Bernini F. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther. 84:1999;413-428.
4. White C.M. Pharmacological effects of HMG CoA reductase inhibitors other than lipoprotein modulation. J Clin Pharmacol. 39:1999;111-118.
5. Axel D.I., Riessen R., Runge H., Viebahn R., Karsch K.R. Effects of cerivastatin on human arterial smooth muscle cell proliferation and migration in transfilter cocultures. J Cardiovasc Pharmacol. 35:2000;619-629.
6. Vincent L., Soria C., Mirshahi F., Opolon P., Mishal Z., Vannier J.P., Soria J., Hong L. Cerivastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme a reductase, inhibits endothelial cell proliferation induced by angiogenic factors in vitro and angiogenesis in in vivo models. Arterioscler Thromb Vasc Biol. 22:2002;623-629.
7. Weis M., Heeschen C., Glassford A.J., Cooke J.P. Statins have biphasic effects on angiogenesis. Circulation. 105:2002;739-745.
8. Sindermann J.R., Fan L., Weigel K.A., Troyer D., Muller J.G., Schmidt A., March K.L., Breithardt G. Differences in the effects of HMG-CoA reductase inhibitors on proliferation and viability of smooth muscle cells in culture. Atherosclerosis. 150:2000;331-341.
9. Guijarro C., Blanco-Colio L.M., Ortego M., Alonso C., Ortiz A., Plaza J.J., Diaz C., Hernandez G., Egido J. 3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ Res. 83:1998;490-500.
10. Kaneider N.C., Reinisch C.M., Dunzendorfer S., Meierhofer C., Djanani A., Wiedermann C.J. Induction of apoptosis and inhibition of migration of inflammatory and vascular wall cells by cerivastatin. Atherosclerosis. 158:2001;23-33.
11. Blanco-Colio L.M., Villa A., Ortego M., Hernandez-Presa M.A., Pascual A., Plaza J.J., Egido J. 3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation. Atherosclerosis. 161:2002;17-26.
12. Baetta R., Donetti E., Comparato C., Calore M., Rossi A., Teruzzi C., Paoletti R., Fumagalli R., Soma M.R. Proapoptotic effect of atorvastatin on stimulated rabbit smooth muscle cells. Pharmacol Res. 36:1997;115-121.
13. Dimitroulakos J., Nohynek D., Backway K.L., Hedley D.W., Yeger H., Freedman M.H., Minden M.D., Penn L.Z. Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: a potential therapeutic approach. Blood. 93:1999;1308-1318.
14. Wong W.W., Tan M.M., Xia Z., Dimitroulakos J., Minden M.D., Penn L.Z. Cerivastatin triggers tumor-specific apoptosis with higher efficacy than lovastatin. Clin Cancer Res. 7:2001;2067-2075.
15. Raff M.C. Social controls on cell survival and cell death. Nature. 356:1992;397-400.
16. Kerkhoff E., Rapp U.R. Cell cycle targets of Ras/Raf signalling. Oncogene. 17:1998;1457-1462.
17. Denhardt D.T. Signal-transducing protein phosphorylation cascades mediated by Ras/Rho proteins in the mammalian cell: the potential for multiplex signalling. Biochem J. 318(Pt 3):1996;729-747.
18. Reed J.C. Bcl-2 family proteins. Oncogene. 17:1998;3225-3236.
19. Johnson G.L., Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK and p38 protein kinases. Science. 298:2002;1911-1912.
20. Chang L., Karin M. Mammalian MAP kinase signalling cascades. Nature. 410:2001;37-40.
21. Cobb M.H. MAP kinase pathways. Prog Biophys Mol Biol. 71:1999;479-500.
22. Xia Z., Dickens M., Raingeaud J., Davis R.J., Greenberg M.E. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science. 270:1995;1326-1331.
23. Rowinsky E.K., Windle J.J., Von Hoff D.D. Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development. J Clin Oncol. 17:1999;3631-3652.
24. Davis R.J. Signal transduction by the JNK group of MAP kinases. Cell. 103:2000;239-252.
25. Bischoff H., Angerbauer R., Bender J., Bischoff E., Faggiotto A., Petzinna D., Pfitzner J., Porter M.C., Schmidt D., Thomas G. Cerivastatin: pharmacology of a novel synthetic and highly active HMG-CoA reductase inhibitor. Atherosclerosis. 135:1997;119-130.
26. Ishiyama M., Miyazono Y., Sasamoto K., Ohkura Y., Ueno K. A highly water-soluble disulfonated tetrazolium salt as a chromogenic indicator for NADH as well as cell viability. Talanta. 44:1997;1299-1305.
27. Takada E., Toyota H., Suzuki J., Mizuguchi J. Prevention of anti-IgM-induced apoptosis accompanying G1 arrest in B lymphoma cells overexpressing dominant-negative mutant form of c-Jun N-terminal kinase 1. J Immunol. 166:2001;1641-1649.
28. Yanase N., Ohshima K., Ikegami H., Mizuguchi J. Cytochrome c release, mitochondrial membrane depolarization, caspase-3 activation, and Bax-alpha cleavage during IFN-alpha-induced apoptosis in Daudi B lymphoma cells. J Interferon Cytokine Res. 20:2000;1121-1129.
29. Alessi D.R., Cuenda A., Cohen P., Dudley D.T., Saltiel A.R. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem. 270:1995;27489-27494.
30. Brinton E.A. Newer HMG-CoA reductase inhibitor (statin) therapies. Clin Cardiol. 24:2001;II-10-3.
31. Bischoff H., Heller A.H. Preclinical and clinical pharmacology of cerivastatin. Am J Cardiol. 82:1998;18J-25J.
32. Liao J. Beyond lipid lowering: the role of statins in vascular protection. Int J Cardiol. 86:2002;5.
33. Xia Z., Tan M.M., Wong W.W., Dimitroulakos J., Minden M.D., Penn L.Z. Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells. Leukemia. 15:2001;1398-1407.
34. Denoyelle C., Vasse M., Korner M., Mishal Z., Ganne F., Vannier J.P., Soria J., Soria C. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis. 22:2001;1139-1148.
35. Casey P.J., Seabra M.C. Protein prenyltransferases. J Biol Chem. 271:1996;5289-5292.
36. Johnson M.D., Woodard A., Okediji E.J., Toms S.A., Allen G.S. Lovastatin is a potent inhibitor of meningioma cell proliferation: evidence for inhibition of a mitogen associated protein kinase. J Neurooncol. 56:2002;133-142.
37. Melchert R.B., Liu H., Granberry M.C., Kennedy R.H. Lovastatin inhibits phenylephrine-induced ERK activation and growth of cardiac. Cardiovasc Toxicol. 1:2001;237-252.
38. Graham T.E., Pfeiffer J.R., Lee R.J., Kusewitt D.F., Martinez A.M., Foutz T., Wilson B.S., Oliver J.M. MEK and ERK activation in ras-disabled RBL-2H3 mast cells and novel roles for geranylgeranylated and farnesylated proteins in Fc epsilonRI-mediated signaling. J Immunol. 161:1998;6733-6744.